Ascites is the abnormal buildup of fluid in the abdominal cavity, commonly linked to liver cirrhosis, heart failure, or cancer. According to Mengying Xu et al., 2024, malignant ascites accounts for approximately 10% of all ascites cases. Current therapies include diuretics, paracentesis, and transjugular intrahepatic portosystemic shunt (TIPS). According to the ascites pipeline analysis by Expert Market Research, growing research focuses on targeted therapies and biologics aimed at improving patient outcomes. Rising liver disease prevalence and oncology advancements are expected to drive significant growth in the ascites treatment landscape in the coming years.
Major companies involved in the ascites pipeline analysis include Wuhan YZY Biopharma Co., Ltd., Versantis AG, and others.
Leading drugs currently in the pipeline include M701, VS-01, and others.
Increasing clinical trials, rising R&D investment in targeted therapies, and the introduction of novel anti-inflammatory and antifibrotic agents are expected to significantly accelerate market expansion in the coming years.
The Ascites Pipeline Analysis Report by Expert Market Research gives comprehensive insights into ascites therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for ascites. The ascites report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The ascites pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with ascites treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to ascites.
Read more about this report - Request a Free Sample
Ascites is the abnormal accumulation of fluid in the peritoneal cavity, usually caused by severe liver disease such as cirrhosis. It occurs when portal hypertension and low albumin levels disrupt fluid balance, leading to fluid leakage from blood vessels into the abdominal cavity.
Ascites treatment focuses on reducing fluid buildup and relieving discomfort. The common approaches include diuretics, paracentesis, sodium restriction, and advanced options like transjugular intrahepatic portosystemic shunt (TIPS) or implantable medical devices. In December 2024, Sequana Medical announced the United States Food and Drug Administration approval of alfapump®, a breakthrough implantable device for recurrent or refractory ascites due to liver cirrhosis. The device automatically transfers excess abdominal fluid to the bladder, reducing the need for paracentesis and improving patients’ quality of life.
According to Mengying Xu et al. (2024), gastric cancer accounts for a significant proportion of malignant ascites cases, with peritoneal metastasis observed in over 50% of patients with distant metastasis. Malignant ascites represents approximately 10% of all ascites cases. Paul Carrier et al. (2024) reported that liver cirrhosis causes about 85% of ascites cases, followed by cancer at 7%, with the remaining cases linked to heart, kidney, or multiple underlying conditions.
This section of the report covers the analysis of ascites drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The ascites pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total ascites clinical trials (at 51%) reflecting strong progress in mid-stage clinical developments for ascites treatment. Phase I accounts for 34%, indicating steady early-stage research activities. Phase III represents 14%, showcasing ongoing advanced trials. Collectively, these phases highlight growing innovation and potential breakthroughs driving advancements in the ascites market.
The drug molecule categories covered under the ascites pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The ascites report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for ascites. Vasopressin receptor modulators are emerging as a promising drug class in the ascites treatment pipeline. For example, Ocelot Bio’s OCE-205, a mixed vasopressin 1a receptor agonist-antagonist peptide, has received orphan drug designation from the United States Food and Drug Administration for the treatment of ascites. The therapy aims to reduce portal hypertension and improve ascitic fluid volume in patients with advanced liver disease.
The EMR report for the ascites pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed ascites therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in ascites clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for ascites. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of ascites drug candidates.
M701 Bispecific Antibody, developed by Wuhan YZY Biopharma Co., Ltd., is under evaluation in a Phase III clinical trial to determine its efficacy and safety in treating malignant ascites caused by advanced epithelial solid tumors. This recombinant human-mouse chimeric antibody targets EpCAM on tumor cells and CD3 on T cells, facilitating immune-mediated tumor destruction. The study is examining M701’s ability to extend puncture-free survival and reduce fluid accumulation, aiming to improve overall patient outcomes.
VS-01 is an innovative liposomal formulation developed by Versantis AG to treat patients with acute-on-chronic liver failure (ACLF) and ascites. In this Phase 2, multi-center, randomized, open-label study (UNVEIL-IT®), the drug is being evaluated for its efficacy, safety, and tolerability when administered intraperitoneally once daily for four days. The study is examining whether VS-01, combined with standard care, is improving clinical outcomes compared to standard therapy alone.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Ascites Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for ascites. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into ascites collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share